507 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
BMY Bristol-Myers Squibb Company $55.14 $90.13B Buy
Article Searches
Nektar (NKTR) Seeks Approval for Analgesic Opioid Candidate http://www.zacks.com/stock/news/306080/nektar-nktr-seeks-approval-for-analgesic-opioid-candidate?cid=CS-ZC-FT-306080 Jun 01, 2018 - Nektar (NKTR) submits NDA to the FDA seeking approval of its analgesic opioid candidate, NKTR-181, for the treatment of chronic low back pain.
Can Nektar Therapeutics Disrupt This $20 Billion Market? https://www.fool.com/investing/2018/05/31/can-nektar-therapeutics-disrupt-this-20-billion-ma.aspx?source=iedfolrf0000001 May 31, 2018 - This company hopes to profit from shaking up how doctors treat lower back pain.
ASCO Conference Preview: Here's What Biotech Investors Need to Watch https://www.fool.com/investing/2018/05/31/asco-preview-heres-what-biotech-investors-need-to.aspx?source=iedfolrf0000001 May 31, 2018 - The biggest cancer meeting of the year is upon us, with updates on clinical trials.
Read This Before You Buy Immuno-Oncology Stocks https://www.fool.com/investing/2018/05/30/read-this-before-you-buy-immuno-oncology-stocks.aspx?source=iedfolrf0000001 May 30, 2018 - The bar for what's considered successful keeps rising, as does the number of potential competitors.
Pfizer's Xalkori Gets Breakthrough Status for New Indications http://www.zacks.com/stock/news/305663/pfizers-xalkori-gets-breakthrough-status-for-new-indications?cid=CS-ZC-FT-305663 May 30, 2018 - Pfizer's (PFE) lung cancer drug, Xalkori (crizotinib), gets Breakthrough Therapy designation by the FDA for two new indications.
5 Best-Selling Orphan Drugs in the U.S. https://www.fool.com/investing/2018/05/30/5-best-selling-orphan-drugs-in-the-us.aspx?source=iedfolrf0000001 May 30, 2018 - These drugs made billions of dollars last year by treating relatively small numbers of patients.
Roche's Tecentriq Study Meets Co-Primary Endpoints for NSCLC http://www.zacks.com/stock/news/305481/roches-tecentriq-study-meets-co-primary-endpoints-for-nsclc?cid=CS-ZC-FT-305481 May 29, 2018 - Roche's (RHHBY) Tecentriq meets its co-primary endpoints of overall survival and progression-free survival in a phase III study for lung cancer.
Why Is Bristol-Myers Squibb (BMY) Up 1.3% Since Its Last Earnings Report? http://www.zacks.com/stock/news/305262/why-is-bristol-myers-squibb-bmy-up-13-since-its-last-earnings-report?cid=CS-ZC-FT-305262 May 28, 2018 - Bristol-Myers Squibb (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AstraZeneca's Imfinzi Improves Survival in Lung Cancer Study http://www.zacks.com/stock/news/305320/astrazenecas-imfinzi-improves-survival-in-lung-cancer-study?cid=CS-ZC-FT-305320 May 28, 2018 - AstraZeneca Plc. (AZN) announces positive overall survival (OS) data from an interim analysis of a phase III PACIFIC study evaluating its oncology candidate, Imfinzi.
Merck's Keytruda Shows Survival Benefit in Squamous NSCLC http://www.zacks.com/stock/news/304903/mercks-keytruda-shows-survival-benefit-in-squamous-nsclc?cid=CS-ZC-FT-304903 May 24, 2018 - Merck's (MRK) Keytruda in combination with chemotherapy demonstrates better OS and PFS in first-line metastatic squamous NSCLC compared to chemotherapy alone.

Pages: 123456...51

Page 1>